Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.78 |
| ▸ | MAOA | P21397 | 2/20 | 0.78 |
| ▸ | PRKCI | P41743 | 1/20 | 0.78 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.72 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.70 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MIF | P14174 | 5/20 | 0.53 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228128 | 0.88 | MAOA (1.00) | MAOBMAOAPRKCIHSD17B1PBRM1 | |
| SCHEMBL3825921 | 0.88 | MAOA (0.92) | MAOBMAOAPRKCIHSD17B1PBRM1 | |
| SCHEMBL5203864 | 0.85 | MAOB (0.69) | MAOBMAOAPRKCIHSD17B1PBRM1 | |
| SCHEMBL9827282 | 0.85 | MAOB (0.58) | MAOBMAOAPRKCIHSD17B1PBRM1 | |
| SCHEMBL1030949 | 0.84 | HSD17B1 (1.00) | MAOBMAOAPRKCIHSD17B1PBRM1 | |
| SCHEMBL784291 | 0.84 | MAOB (0.59) | MAOBMAOAPRKCIHSD17B1PBRM1 | |
| SCHEMBL28880 | 0.83 | PBRM1 (1.00) | MAOBMAOAPRKCIHSD17B1PBRM1 | |
| SCHEMBL30137886 | 0.83 | PBRM1 (1.00) | MAOBMAOAPRKCIHSD17B1PBRM1 | |
| SCHEMBL6200904 | 0.81 | MAOB (0.54) | MAOBMAOAPRKCIHSD17B1PBRM1 | |
| SCHEMBL23142696 | 0.81 | MAOB (0.58) | MAOBMAOAPRKCIHSD17B1PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 660 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| CN-117757175-A | flame-retardant polymer composition for new energy vehicle and production process thereof | 河南云瀚实业有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-114436995-B | Morpholine-indenone-chalcone derivative fluorescent probe and preparation method and application thereof | 河南理工大学 | 2023-04-25 | — | — | CN | claimed |
| CN-111171809-B | Hydroxyl indenone derivative fluorescent probe and preparation method and application thereof | 广州大学 | 2022-12-27 | — | — | CN | claimed |
| CN-114436995-A | Morpholine-indanone-chalcone derivative fluorescent probe and preparation method and application thereof | 河南理工大学 | 2022-05-06 | — | — | CN | claimed |
| CN-108558627-B | Method for preparing 5-hydroxy-1-indanone | 山西大学 | 2020-09-29 | — | — | CN | claimed |
| CN-111171809-A | Hydroxyl indenone derivative fluorescent probe and preparation method and application thereof | 广州大学 | 2020-05-19 | — | — | CN | claimed |
| US-10092786-B2 | Fire extinguishing composition comprising aldoketones compound | XI'AN WESTPEACE FIRE TECHNOLOGY CO., LTD. (CN) | 2018-10-09 | — | — | US | claimed |
| US-20160332016-A1 | Fire Extinguishing Composition Comprising Aldoketones Compound | NANO FIRE, LLC | 2016-11-17 | — | — | US | claimed |
| US-20260146026-A1 | COMPOUND, COMPOSITION, CURED PRODUCT, METHOD FOR PRODUCING CURED PRODUCT, AND METHOD FOR PRODUCING ELECTRONIC COMPONENT | ADEKA CORPORATION (JP) | 2026-05-28 | — | — | US | disclosed |
| US-20260079084-A1 | COMPOUND, EXTRACELLULAR VESICLE STAINING AGENT, AND FLUORESCENT STAINING METHOD FOR EXTRACELLULAR VESICLES | NATIONAL UNIV CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2026-03-19 | — | — | US | disclosed |
| US-20260022094-A1 | Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4610254-A1 | COMPOUND, COMPOSITION, CURED PRODUCT, METHOD FOR PRODUCING CURED PRODUCT, AND METHOD FOR PRODUCING ELECTRONIC COMPONENT | ADEKA CORPORATION (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-4291050-A | DIURETICS, ANTIEDEMIC AGENTS, HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1981-09-22 | — | — | US | disclosed |
| US-4291168-A | DIURETICS | MEAD JOHNSON & COMPANY (US) | 1981-09-22 | — | — | US | disclosed |
| US-4247715-A | BIURETICS | MEAD JOHNSON & COMPANY (US) | 1981-01-27 | — | — | US | disclosed |
| US-4247715-A | BIURETICS | MEAD JOHNSON & COMPANY (US) | 1981-01-27 | — | — | US | disclosed |
| US-4109088-A | ANTIDEPRESSANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1978-08-22 | — | — | US | disclosed |
| US-3931239-A | DIURETIC, HYPOTENSIVE | MERCK & CO., INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | MAOB 3576/4885MAOA 3647/4885PRKCI 1088/4885 |
| US-20260079084-A1 | COMPOUND, EXTRACELLULAR VESICLE STAINING AGENT, AND FLUORESCENT STAINING METHOD FOR EXTRACELLULAR VESICLES | EXOSC4, CHMP4B, EXOSC5 | MAOB 2135/4885MAOA 2773/4885PRKCI 4201/4885 |
| US-20260146026-A1 | COMPOUND, COMPOSITION, CURED PRODUCT, METHOD FOR PRODUCING CURED PRODUCT, AND METHOD FOR PRODUCING ELECTRONIC COMPONENT | CBR3, CBR1, NOTUM | MAOB 878/4885MAOA 959/4885PRKCI 3265/4885 |
| US-20260022094-A1 | Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, CLN6, S1PR1 | MAOB 1817/4885MAOA 1702/4885PRKCI 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.